Table 1.
Clinicopathological Data, ALK Expression, and ALK Fusion Events in 11 IMTs
| Case no. | Age/sex | Tumor location | ALK expression | ALK fusion* |
|---|---|---|---|---|
| 1 | 1 /M | Abdomen | Cytoplasmic | TPM4-ALK |
| 2 | 30 /F | Lung | Cytoplasmic | TPM3-ALK |
| 3 | 23 /F | Abdomen | Cytoplasmic | TPM3-ALK |
| 4 | 8 /M | Abdomen | Cytoplasmic | – |
| 5 | 1 /F | Abdomen | Cytoplasmic | – |
| 6 | 27 /M | Femur | Cytoplasmic | – |
| 7 | 4 /M | Abdomen | Nuclear | – |
| 8 | 40 /M | Paratesticular | – | – |
| 9 | 50 /M | Abdomen | – | – |
| 10 | 50 /F | Lung | – | – |
| 11 | 40 /M | Femur | – | – |
IMT, Inflammatory myofibroblastic tumor; –, not detected.
*By RT-PCR screening for TPM4-ALK and TPM3-ALK.